|Bid||95.03 x 1100|
|Ask||95.13 x 900|
|Day's Range||94.74 - 95.96|
|52 Week Range||73.05 - 97.31|
|PE Ratio (TTM)||72.16|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||99.00|
PRA Health Sciences, a large contract research company, will expand its Kansas City footprint with a new lab in Lenexa.
PRA Health's (PRAH) shares gain from better-than-expected Q1 earnings. However, increasing labor-related costs in the Clinical Research wing is a headwind.
NEW YORK , May 25, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: S&P MidCap 400 constituent ABIOMED Inc. (NASD: ABMD) will ...
PRA Health Sciences, Inc. (PRAH) is pleased to announce it was recognized by PharmaTimes as the International Clinical Research Company of the Year. This is the fifth year in a row that PRA has received this award. "This award celebrates excellence in the clinical research industry and we are honored to once again be recognized by our peers," said Colin Shannon, President and Chief Executive Officer.
PRA Health Sciences, Inc. (PRAH) is pleased to announce it was recognized by PharmaTimes as the International Clinical Research Company of the Year. “This award celebrates excellence in the clinical research industry and we are honored to once again be recognized by our peers,” said Colin Shannon, President and Chief Executive Officer. PRA also swept the Clinical Research Associate and Clinical Trial Administrator categories capturing a total of 11 awards.
On May 16, IQVIA Holdings’ (IQV) closing price was $99.3, almost 2.9% lower than its closing price on May 15. This fall was attributable to concerns raised by the FDA related to inaccuracies in sales data given to the FDA by IQVIA, which included data about certain opioid drug products. The FDA has been using data from IQVIA to understand the scale of opioid use and to estimate the future requirement of these drugs.
NEW YORK, May 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The ...
PRA Health Sciences, Inc. (PRAH) is pleased to announce it was recognized as the Clinical Research Company of the Year—Americas by PharmaTimes. “We are honored to once again receive this award,” said Michael Brooks, Executive Vice President, Product Registration, Americas. Organized by PharmaTimes, the Clinical Researcher of the Year competition is considered a key barometer of quality standards in the contract research organization (CRO) industry.
Longtime PRA Health Sciences' Chief Financial Officer Linda Baddour is retiring as the Raleigh-based contract research organization sees a strong start to 2018.
The Raleigh, North Carolina-based company said it had net income of 59 cents per share. Earnings, adjusted for one-time gains and costs, came to 85 cents per share. The results exceeded Wall Street expectations. ...
Severe flu activity in the first quarter should benefit companies in the health care space, while insurers might feel the pinch from the same.
RALEIGH, N.C., April 12, 2018-- PRA Health Sciences, Inc. will release its first quarter 2018 results after the market closes on Wednesday, April 25, 2018. The Company will also host a conference call ...
From BioDelivery Sciences International to Red Hat, insiders at Triangle companies raked in millions in the first three months of 2018, public records show.
For Kent Thoelke, the job of PRA Health Sciences Inc (NASDAQ: PRAH )’s chief scientific officer is part drug development, part social media management. The disparate responsibilities seem to have disparate ...
PRA Health Sciences, just voted the Best CRO in Asia, may soon put its new buy point on trial.
RALEIGH, N.C., March 06, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is honored to once again be named Best CRO in Asia. PRA received this recognition at the Phar-East Pharma and Biotech ...